GlassScriptPhysician profile
Chelsea Lane Gondek
NPI 1013474352
$2,066.34
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,015 · 2022: $985 · 2023: $20.48 · 2024: $46.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.99 | 2021-2022 | |
| Novo Nordisk INC | $262.29 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $145.45 | 2021 | |
| Lilly USA, LLC | $137.05 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $133.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.91 | 2021-2022 | |
| Akcea Therapeutics, INC. | $116.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $92.35 | 2021-2022 | |
| Amgen INC. | $76.22 | 2021-2024 | Evenity, Prolia |
| Pfizer INC. | $73.98 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $54.81 | 2022 | |
| Astellas Pharma US INC | $54.31 | 2021 | |
| Amarin Pharma, INC. | $47.63 | 2021 | |
| Sanofi-Aventis U.S. LLC | $43.14 | 2021-2022 | |
| Zoll Respicardia, INC. | $42.35 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36.54 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.24 | 2022 | |
| Eisai INC. | $28.88 | 2021 | |
| Almatica Pharma LLC | $27.19 | 2022 | |
| Arbor Pharmaceuticals, INC. | $25.08 | 2021 | |
| Abbott Laboratories | $24.16 | 2024 | Freestyle Libre 2 |
| Harmony Biosciences LLC | $22.57 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.44 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.96 | 2021 | |
| Melinta Therapeutics, LLC | $20.48 | 2023 | Rezzayo |
| Otsuka America Pharmaceutical, INC. | $17.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.44 | 2022 | |
| Esperion Therapeutics, INC. | $17.25 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.33 | 2022 | |
| Genentech USA, INC. | $8.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Gondek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.